6.85  -0.14 (-2%)		06-20 16:00
Open: 6.795 High: 6.965 Volume: 62,803		Pre. Close: 6.99 Low: 6.735 Market Cap: 60(M)

Short term
Mid term
Targets	6-month :	9.48	1-year :	10.48
Resists	First :	8.12	Second :	8.97
Pivot price	7.42
Supports	First :	6.73	Second :	5.6
MAs	MA(5) :	7.05	MA(20) :	7.59
	MA(100) :	6.81	MA(250) :	9.7
MACD	MACD :	-0.5	Signal :	-0.4
%K %D	K(14,3) :	10.3	D(3) :	14.3
RSI	RSI(14): 36.5
52-week	High :	20.62	Low :	1.79

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ CRVO ] has closed above bottom band by 6.5%. Bollinger Bands are 61.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	6.97 - 7.03	7.03 - 7.07
Low:	6.62 - 6.68	6.68 - 6.72
Close:	6.77 - 6.87	6.87 - 6.93

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

Tue, 10 Jun 2025
CervoMed (CRVO) Strengthens Leadership with Key Executive Appointment | CRVO Stock News - GuruFocus

Tue, 10 Jun 2025
CervoMed Accelerates Phase 3 DLB Drug Development With Key Manufacturing Expert Hire - Stock Titan

Mon, 12 May 2025
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

Mon, 12 May 2025
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire

Sat, 22 Mar 2025
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats - Seeking Alpha

Wed, 19 Mar 2025
Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts? - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	9 (M)
Shares Float	5 (M)
Held by Insiders	33.3 (%)
Held by Institutions	26.3 (%)
Shares Short	896 (K)
Shares Short P.Month	972 (K)

EPS	-2.18
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.98
Profit Margin	-200.6 %
Operating Margin	-276.6 %
Return on Assets (ttm)	-56.2 %
Return on Equity (ttm)	-93.5 %
Qtrly Rev. Growth	-18.3 %
Gross Profit (p.s.)	-1.33
Sales Per Share	1.07
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-19 (M)
Levered Free Cash Flow	-12 (M)

PE Ratio	-3.16
PEG Ratio	0
Price to Book value	1.72
Price to Sales	6.4
Price to Cash Flow	-3.14

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.